Primary and secondary outcome measures intention-to-treat analysis*
| Cephalexin (n=24) | Placebo (n=28) | Risk difference (95% CI) | p Value | |
|---|---|---|---|---|
| Number of infections | 3 | 10 | 0.35 (0.11 to 1.13) | 0.064 |
| Infection rate (95% CI) | 12.5 (2.7 to 32.4) | 35.7 (18.6 to 55.9) | NA | |
| Prescription of antibiotics | 3 | 6 | 0.58 (0.16 to 2.09) | 0.480 |
| Number of additional follow-up visits required | ||||
| Median | 0 [0–0] | 0 [0–1] | NA | 0.164 |
| Total (Range) | 7 (0–3) | 26 (0–10) | NA | |
| Additional total amount of antibiotics (excluding prophylaxis) (mg)† | ||||
| Median | 0 [0–0] | 0 [0–0] | NA | 0.290 |
| Total (Range) | 27 000 (0–12 000) | 146 750 (0–66 750) | NA | |
*Data are median (IQR) (range) or number (%) unless otherwise stated; 95% CI for infection rate are the Clopper-Pearson interval; p values are Fisher’s exact test or the Mann-Whitney U test for categorical and continuous variables, respectively.
†Cephalexin group: cephalexin (15 000 mg), flucloxacillin (12 000 mg); placebo group: cephalexin (100 000 mg), flucloxacillin (24 000 mg); ciprofloxacin (14 000 mg), amoxicillin/clavulonic acid (8750 mg).
NA, not applicable.